| ACTH | Adrenocorticotropic hormone |
| BORR | Best observed response |
| CR | Complete remission |
| FT4 | Free-T4 (tetraiodothyronine) |
| DOB | Date of birth |
| HIPAA | Health Insurance Portability and Accountability Act |
| ICI | Immune checkpoint inhibitors |
| I+N | Ipilimumab plus nivolumab |
| irAE | Immune-related adverse events |
| IRB | Institutional review board |
| LAG-3 | Lymphocyte-activation gene 3 |
| LDH | Lactate dehydrogenase |
| N+R | Nivolumab plus relatlimab |
| OS | Overall survival |
| PFS | Progression-free survival |
| PD | Progressive disease |
| PR | Partial response |
| SD | Stable disease |
| Tg | Thyroglobulin |
| TPO | Thyroid peroxidase |
| TSH | Thyroid stimulating hormone |
| TSHR | Thyroid stimulating hormone receptor |